DELEGATE BROCHURE

CPD GURUKUL

TRANSPLANT CONNECT


Early Introduction of Everolimus With CNI Minimisation Strategy Post Renal Transplantation

A Focused Academic Programme in Renal Transplantation

Modnay, 16th November 2026

1:00 PM – 2:30 PM

Seminar Hall,
Nizam's Institute of Medical Sciences (NIMS),
Hyderabad



Welcome Letter

Dear Doctor,

Warm greetings from **CPD Gurukul**

We are pleased to invite you to Early Introduction of Everolimus with CNI Minimisation Strategy Post Renal Transplantation, a focused academic programme designed to facilitate discussion on an important consideration in post-kidney transplant care: optimising immunosuppressive therapy while minimising calcineurin inhibitor (CNI)-associated nephrotoxicity.

Advances in renal transplantation and immunosuppressive therapy have substantially improved short-term graft survival. However, maintaining long-term allograft function remains a clinical challenge, particularly when prolonged exposure to CNIs contributes to nephrotoxicity and other treatment-related complications.

Everolimus, an mTOR inhibitor, has emerged as an important component of selected immunosuppressive regimens, allowing reduced CNI exposure while maintaining adequate immunosuppression in appropriately selected renal transplant recipients. The timing of introduction, patient selection, immunological risk, therapeutic drug monitoring and management of adverse effects remain important considerations in clinical practice.

The programme will examine the clinical rationale and available evidence supporting early everolimus introduction with CNI minimisation, discuss practical considerations in treatment selection and explore strategies for balancing rejection prevention, treatment safety and long-term graft preservation.

Dr. D. Sree Bhushan Raju, Nephrologist, will lead the academic session, followed by an interactive clinical discussion and Q&A.

We look forward to your active participation and valuable contribution to this academic exchange.

Warm regards,



Dr. Sunil Pandey
Director – Medical Affairs

Academic Importance of the Programme

- Kidney transplantation offers patients with end-stage kidney disease an opportunity for improved survival and quality of life. However, long-term transplant success requires effective immunosuppression while minimising treatment-related toxicity and preserving renal allograft function.
- Calcineurin inhibitors, including tacrolimus and cyclosporine, remain central to maintenance immunosuppression. Although effective in preventing acute rejection, CNI exposure may contribute to nephrotoxicity and other adverse effects. Reducing CNI exposure without increasing immunological risk is therefore an important therapeutic consideration.
- Early Introduction of Everolimus with CNI Minimisation Strategy Post Renal Transplantation has been designed to examine the clinical evidence, appropriate patient selection, treatment monitoring and practical considerations associated with early everolimus-based immunosuppressive strategies.

Key Areas of Academic Focus

- Contemporary approaches to maintenance immunosuppression after kidney transplantation
- Clinical implications of acute and chronic CNI-associated nephrotoxicity
- Mechanism of action and immunosuppressive role of everolimus
- Rationale for early everolimus introduction with reduced CNI exposure
- Evidence from clinical studies evaluating everolimus-based regimens
- Patient selection and immunological risk assessment
- Timing of everolimus initiation following transplantation
- Therapeutic drug monitoring of everolimus and CNIs
- Management of proteinuria, wound-healing complications and other adverse effects
- Long-term renal allograft surveillance and preservation of graft function

Scientific Discussion Domains

Understanding CNI-Associated Nephrotoxicity: Examining the clinical implications of CNI exposure, mechanisms of renal injury and challenges in differentiating drug-related nephrotoxicity from other causes of allograft dysfunction.

Rationale for Early Everolimus Introduction: Reviewing the pharmacological basis and clinical evidence for introducing everolimus with reduced CNI exposure following kidney transplantation.

Patient Selection and Timing: Discussing immunological risk, graft function, wound-healing status, proteinuria and other factors influencing suitability for an everolimus-based regimen.

Balancing Rejection Prevention and Treatment Safety: Evaluating the potential benefits and limitations of CNI minimisation while maintaining adequate immunosuppressive protection.

Therapeutic Drug Monitoring: Understanding the importance of monitoring everolimus and CNI exposure, renal function and treatment-related adverse effects.

Long-Term Graft Preservation: Integrating individualised immunosuppressive therapy, clinical monitoring and appropriate follow-up into strategies aimed at maintaining long-term renal allograft function.

AGENDA

1:00 PM – 2:30 PM

Time	Topic
01:00–01:10 PM	Welcome Address & Programme Introduction: Setting the Context: Optimising Immunosuppression and Minimising CNI Exposure Following Renal Transplantation
01:10–01:50 PM	Expert Faculty Session: Early Introduction of Everolimus with CNI Minimisation Strategy Post Renal Transplantation. Dr. D. Sree Bhushan Raju, Nephrologist
01:50–02:20 PM	Interactive Expert Discussion & Q&A: From Early Everolimus Introduction to Clinical Decisions: Balancing Rejection Risk, Treatment Safety and Long-Term Graft Protection
02:20–02:30 PM	Key Takeaways, Closing Remarks & Vote of Thanks
02:30 PM onwards	Lunch

Discussion Focus

- Clinical rationale for early everolimus introduction after kidney transplantation
- Recognising CNI-associated nephrotoxicity and its implications for graft function
- Identifying suitable candidates for everolimus-based immunosuppressive strategies
- Optimal timing of everolimus initiation and CNI dose reduction
- Interpreting clinical evidence on rejection rates and renal function outcomes
- Balancing immunological risk with reduced CNI exposure
- Monitoring everolimus and CNI trough concentrations
- Recognising and managing proteinuria, wound-healing complications, dyslipidaemia and other adverse effects
- Individualising immunosuppression and improving long-term graft outcomes

Learning Objectives

By the end of the programme, participating delegates should be able to:

- Explain the role of CNIs in maintenance immunosuppression and recognise important clinical implications of CNI-associated nephrotoxicity.
- Discuss the mechanism of action and clinical rationale for everolimus-based immunosuppressive strategies.
- Examine evidence supporting early everolimus introduction with reduced CNI exposure in selected renal transplant recipients.
- Identify clinical and immunological factors influencing patient selection and timing of treatment initiation.
- Discuss the principles of CNI minimisation while maintaining adequate protection against acute rejection.
- Recognise the importance of therapeutic drug monitoring during everolimus-based treatment.
- Identify important adverse effects and safety considerations associated with everolimus therapy.
- Apply an individualised approach to immunosuppressive optimisation, treatment monitoring and long-term renal allograft surveillance.

Why this Programme Matters

Reducing CNI Exposure Examines the clinical rationale for minimising CNI exposure while maintaining adequate immunosuppression following kidney transplantation.

Evidence-Based Perspective Reviews contemporary clinical evidence regarding early everolimus introduction, rejection prevention, renal function and treatment-related outcomes.

Individualised Treatment Highlights the importance of patient selection, immunological risk assessment and appropriate timing when considering everolimus-based strategies.

Clinical Applicability Focuses on practical aspects of immunosuppressive management, therapeutic drug monitoring, adverse-effect recognition and long-term graft surveillance.

Interactive Learning Provides delegates with an opportunity to discuss evolving evidence, clinical uncertainties and practical approaches with expert faculty.

Expert Faculty

Dr. D. Sree Bhushan Raju

Dr. D. Sree Bhushan Raju will lead the scientific discussion on early introduction of everolimus with CNI minimisation following renal transplantation.

The session will focus on the clinical rationale and evidence supporting everolimus-based immunosuppressive strategies, appropriate patient selection, balancing rejection prevention with treatment safety, therapeutic drug monitoring and long-term renal allograft preservation.

His academic presentation will be followed by an interactive discussion addressing practical challenges in post-transplant immunosuppressive management.

Detailed qualifications, current designation and professional biography to be incorporated following faculty confirmation.

Target Audience

- Nephrologists
- Renal Transplant Physicians
- Renal Transplant Surgeons
- Transplant Nephrology Faculty & Consultants
- DM/DNB Nephrology Residents
- Physicians involved in renal transplant follow-up
- Renal Transplant Coordinators
- Healthcare professionals involved in post-transplant care

Limited Seats – Book Early!

This focused academic programme aims to encourage participation and clinical interaction among healthcare professionals involved in kidney transplantation, immunological risk assessment, desensitisation strategies and long-term transplant recipient care.

Registration Fees (inclusive of GST)		
Category	Up to 1st November 2026	Spot Registration
DM / DNB Nephrology Resident	INR 300	INR 500
DM / DNB Resident (Other Institutes)	INR 500	INR 700
Faculty / Consultant	INR 1000	INR 1250

Delegate Participation Benefits

Registered delegates will receive:

- Delegate scientific kit and educational resources
- Access to all scientific sessions
- Participation in faculty-led discussions and interactive case reviews
- Collaborative peer-learning opportunities
- Hospitality during the scientific programme
- Networking opportunities with experienced faculty members and practising clinicians
- Post-event scientific highlights and educational resources

About CPD Gurukul

CPD Gurukul LLP is a continuing professional development and medical education platform focused on developing and executing structured scientific learning programmes for healthcare professionals.

Through multi-city CPD programmes, scientific meetings, expert-led discussions and clinically relevant educational initiatives, CPD Gurukul aims to facilitate evidence-based learning and practical knowledge exchange among healthcare professionals.

Academic Activities Include

- Continuing Professional Development programmes
- Multi-city medical education initiatives
- Speciality-focused scientific meetings
- Faculty-led clinical discussions
- Case-based learning programmes
- Clinical education and knowledge-sharing initiatives

For inquiries and registration, please contact:

Dr. Sunil Pandey
Director, Medical Affairs

Mob - 9820481893
Email - drsunilpandey@cpdgurukul.in
Website - www.cpdgurukul.in